Global Selective Cox-2 Inhibitors Market Growth (Status and Outlook) 2023-2029

Global Selective Cox-2 Inhibitors Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Selective Cox-2 Inhibitors Industry Forecast” looks at past sales and reviews total world Selective Cox-2 Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Selective Cox-2 Inhibitors sales for 2023 through 2029. With Selective Cox-2 Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Selective Cox-2 Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Selective Cox-2 Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Selective Cox-2 Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Selective Cox-2 Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Selective Cox-2 Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Selective Cox-2 Inhibitors.

The global Selective Cox-2 Inhibitors market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Selective Cox-2 Inhibitors is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Selective Cox-2 Inhibitors players cover Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla and Glenmark Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Selective Cox-2 Inhibitors market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other

Segmentation by application
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Takeda
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals 

Please note: The report will take approximately 2 business days to prepare and deliver.